Roberta Rondena

🤩 Delighted to share that, today, the European Medicines Agency has granted approval to Servier’s first targeted therapy for patients with glioma.  ✅ This approval is based on robust clinical data, demonstrating a significant step forward in the treatment of a rare brain cancer.  ✅ It’s also a strong recognition of our scientific capabilities and the unfailing work of our R&D teams, who are committed to advancing precision medicine in oncology.  Proud to see our research contribute to transforming patient outcomes.  #Oncology #Glioma #RnD #WeAreServier 

696

33 commenti

Three more JCA candidates have been named by the European Commission, bringing the total to six. The latest additions to the list are Novartis’ onasemnogene abeparvovec (OAV101 IT) for 5q spinal muscular atrophy, PharmaMar’s lurbinectedin for lung cancer and AstraZeneca’s camizestrant for locally advanced or metastatic breast cancer. OAV101 IT will have the NCPE in Ireland as its assessor and HAS in France as its co-assessor. For lurbinectedin, the assessor will be IQWiG in Germany and the co-assessor will be INFARMED in Portugal. The Österreichische Sozialversicherung (Federation of Social Insurances) in Austria will be the assessor for camizestrant, while RIZIV-INAMI in Belgium will be the co-assessor. Nine HTA agencies are playing leading roles in the first six JCAs. Three—IQWiG, HAS and the NCPE—are each already participating in two assessments. Two products—autologous melanoma-derived tumour-infiltrating lymphocytes and onasemnogene abeparvovec (OAV101 IT) are classified as ATMPs. OAV101 IT is notable as the first non-oncology drug to enter the JCA process. It is an intrathecal formulation of onasemnogene abeparvovec, which has been available as an intravenous formulation (Zolgensma) for the treatment of spinal muscular atrophy since May 2020. The new formulation is intended to treat older patients and is optimised to target motor neurons in the spinal cord. #EU #JCA #onasemnogene #lurbinectedin #camizestrant

348

4 commenti

🔬 Remarkable strides and urgent gaps in the fight against lung cancer   Over the last decade, we’ve witnessed a transformation in the lung cancer treatment landscape. But despite these advances, many patients and families are still left with unmet needs. Let´s have a look at it:   From one-size-fits-all to precision medicine Thanks to targeted therapies and immunotherapies, we are now routinely matching treatments to molecular profiles (EGFR, ALK, ROS1, KRAS, etc.). These “precision” approaches have significantly improved survival, even for metastatic non-small cell lung cancer. These advances underscore that lung cancer is no longer a monolithic disease - we are steadily turning it into a constellation of molecularly defined subtypes, each with its own therapeutic roadmap.   But the unmet need is still very high Studies show that ~80% of lung cancer patients report at least one unmet supportive care need, with psychological and informational needs being among the most common.  In short: even as we unlock more precise therapies, many patients and caregivers are left navigating emotional, social, and practical challenges - sometimes far beyond what the clinic can deliver.   💡 Bottom line (for me and, I hope, for us all): We must continue pushing the frontier of innovative therapies - but we cannot forget the human side. Research, policy, and care models need to evolve in parallel: to anticipate and deliver on what patients and families truly need.   If you’re working in lung cancer care, research, patient advocacy, or policy, I’m always eager to connect and learn: See you hopefully at ESMO congress in Berlin!   #LungCancer #MyCompany #PrecisionMedicine #Oncology #PatientCare #ESMO26 #CancerResearch #FlatWhiteBerlin

144

6 commenti

“There are too many patients suffering from dermatological diseases who have never seen a dermatologist.” This impactful sentiment from Rudy Anderson, CAE of the American Academy of Dermatology (AAD), who joined my Sanofi colleague Mike Sibley for a conversation as part of the Patient Advocacy Voices video series. In their discussion, Rudy speaks candidly about the urgent need to close gaps in dermatologic care and how AAD is working to close those gaps through advocacy, education, research, and partnerships. Rudy also shared some of the exciting work AAD is doing to support dermatologists and help ensure that more patients living with dermatologic diseases are heard and receive the treatments they need. 👉 Watch the full conversation: https://lnkd.in/eT-GMsKc #PatientAdvocacy #PatientEngagement #PatientAdvocacyVoices #Dermatology 

97

5 commenti